Effects of Differing Nutritional Supplementation Combined With High-Intensity Aerobic Interval Training on Functional Exercise Capacity, Cardiac Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Trial.

Am J Phys Med RehabilDec 29, 2025 (epub)
Clinical ResearchCardiology

Ivo Petrov, Kamen Stoichev, Okan Aliman et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized trial compared two nutritional supplementation strategies alongside 12 weeks of group-based high-intensity aerobic interval training in 68 patients with heart failure with reduced ejection fraction. Participants received either creatine, D-ribose, coenzyme Q10, and vitamin E or ubiquinol and D-ribose. The multi-ingredient group had significantly greater improvements across functional exercise capacity, health-related quality of life, left ventricular ejection fraction, and perceived exertion (P < 0.05). The largest reported functional measure changes were a 25.46% increase in peak VO₂ and a 19.88% increase in 6-minute walk test performance.

Key findings

  • Compared with ubiquinol plus D-ribose, the multi-ingredient group improved 6-minute walk test performance by +19.88% and peak VO₂ by +25.46%.
  • The multi-ingredient group had greater improvement in left ventricular ejection fraction (+40.94%) and health-related quality of life (-25.64%).
  • Perceived exertion decreased by -38.53% in the multi-ingredient group relative to the comparator (P < 0.05).

Why it matters

The findings suggest that, during structured high-intensity interval training, the choice of nutritional supplement may be associated with differences in exercise capacity and other patient-relevant outcomes in heart failure with reduced ejection fraction. The results are relevant to evaluating adjunctive strategies, but do not establish the effects of supplementation without training or whether these changes translate into longer-term clinical outcomes.

What to keep in mind

Both groups undertook high-intensity interval training, so the abstract does not establish supplementation effects independent of training. Follow-up was limited to the 12-week intervention.

Source

Published in Am J Phys Med Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.